|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
52,775,000 |
Market
Cap: |
N/A |
Last
Volume: |
1,247,701 |
Avg
Vol: |
599,363 |
52
Week Range: |
$10.49 - $10.49 |
|
Level
I Sector: |
Information Technology |
Level
II Sector: |
Electronics |
Level
III Sector: |
Scientific & Technical Instruments |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) ![](../../images/information.jpg) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-03-28 |
2023-12-26 |
2023-06-27 |
2022-06-27 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Hrusovsky E Kevin |
President & CEO |
|
2011-03-03 |
4 |
D |
$6.76 |
$0 |
D/D |
(0) |
621,837 |
|
- |
|
Kruka William C. |
Sr VP Corporate Development |
|
2011-03-03 |
4 |
D |
$6.76 |
$27,588 |
D/D |
(4,081) |
76,926 |
|
- |
|
Manyak David M |
Exec VP, Drug Discovery Svcs |
|
2011-03-03 |
4 |
D |
$6.76 |
$24,924 |
D/D |
(3,687) |
495,212 |
|
- |
|
Mcaree Peter F |
Sr.VP and CFO |
|
2011-03-03 |
4 |
D |
$6.76 |
$21,443 |
D/D |
(3,172) |
69,886 |
|
- |
|
Bal Bruce J |
Sr.VP, Operations |
|
2011-03-03 |
4 |
D |
$6.76 |
$21,166 |
D/D |
(3,131) |
123,208 |
|
- |
|
Creager Stephen E |
Sr. VP and General Counsel |
|
2011-03-03 |
4 |
D |
$6.76 |
$27,824 |
D/D |
(4,116) |
71,104 |
|
- |
|
Carter David Warren |
Director |
|
2011-03-02 |
4 |
S |
$6.51 |
$185,424 |
I/I |
(28,483) |
0 |
|
- |
|
Mcaree Peter F |
Sr.VP and CFO |
|
2011-02-28 |
4 |
D |
$6.69 |
$4,810 |
D/D |
(719) |
63,433 |
|
- |
|
Kruka William C. |
Sr VP Corporate Development |
|
2011-02-28 |
4 |
D |
$6.69 |
$10,102 |
D/D |
(1,510) |
69,882 |
|
- |
|
Bal Bruce J |
Sr.VP, Operations |
|
2011-02-28 |
4 |
D |
$6.69 |
$9,025 |
D/D |
(1,349) |
116,714 |
|
- |
|
Manyak David M |
Exec VP, Drug Discovery Svcs |
|
2011-02-28 |
4 |
D |
$6.69 |
$7,399 |
D/D |
(1,106) |
487,774 |
|
- |
|
Creager Stephen E |
Sr. VP and General Counsel |
|
2011-02-28 |
4 |
D |
$6.69 |
$10,463 |
D/D |
(1,564) |
64,095 |
|
- |
|
Hrusovsky E Kevin |
President & CEO |
|
2011-02-23 |
4 |
OE |
$6.57 |
$164,250 |
D/D |
25,000 |
559,337 |
|
- |
|
Bal Bruce J |
Sr.VP, Operations |
|
2011-02-23 |
4 |
D |
$6.57 |
$11,813 |
D/D |
(1,798) |
114,313 |
|
- |
|
Kruka William C. |
Sr VP Corporate Development |
|
2011-02-23 |
4 |
D |
$6.57 |
$16,898 |
D/D |
(2,572) |
67,642 |
|
- |
|
Mcaree Peter F |
Sr.VP and CFO |
|
2011-02-23 |
4 |
D |
$6.57 |
$12,995 |
D/D |
(1,978) |
62,152 |
|
- |
|
Griffith Joseph H. Iv |
VP, Finance & Controller |
|
2011-02-23 |
4 |
D |
$6.57 |
$5,906 |
D/D |
(899) |
28,518 |
|
- |
|
Manyak David M |
Exec VP, Drug Discovery Svcs |
|
2011-02-23 |
4 |
D |
$6.57 |
$11,813 |
D/D |
(1,798) |
485,880 |
|
- |
|
Creager Stephen E |
Sr. VP and General Counsel |
|
2011-02-23 |
4 |
D |
$6.57 |
$13,521 |
D/D |
(2,058) |
61,909 |
|
- |
|
Mcaree Peter F |
Sr.VP and CFO |
|
2011-01-18 |
4 |
AS |
$6.49 |
$48,650 |
D/D |
(7,500) |
58,630 |
|
- |
|
Creager Stephen E |
Sr. VP and General Counsel |
|
2011-01-18 |
4 |
AS |
$6.44 |
$64,448 |
D/D |
(10,000) |
58,967 |
|
- |
|
Manyak David M |
Exec VP, Drug Discovery Svcs |
|
2010-11-24 |
5 |
GD |
$0.00 |
$0 |
D/D |
8,000 |
482,723 |
|
- |
|
Bishop Robert C |
Director |
|
2010-11-23 |
5 |
GD |
$0.00 |
$0 |
D/D |
7,288 |
20,564 |
|
- |
|
Carter David Warren |
Director |
|
2010-11-02 |
4 |
S |
$4.50 |
$42,906 |
I/I |
(9,495) |
28,483 |
|
- |
|
Manyak David M |
Exec VP, Drug Discovery Svcs |
|
2010-10-15 |
4 |
AS |
$4.24 |
$16,960 |
D/D |
(4,000) |
490,723 |
|
- |
|
291 Records found
|
|
Page 3 of 12 |
|
|